Global Genital Herpes Treatment 麻豆原创 2022-2032 by Virus Type , Drug Type , Route of Administration , Patient Gender , Distribution Channel , and Region: Trend Forecast and Growth Opportunity

Publication ID:

GRM0223037

Publication Date:

February 28, 2023

Pages:

168

Publisher:

Grace 麻豆原创 Data

Countries:

Global [1]

USD 3,400.00

Medical Devices [2]

Diagnostics [3]

Country Overview (Pharma & Healthcare) [4]

Pharma & Healthcare [5]

Description:

Global genital herpes treatment market will reach $5,051.8 million by 2032, growing by 4.7% annually over 2022-2032, driven by the rising prevalence of sexually transmitted diseases, changing socio-cultural openness, increasing awareness about HSV infection and its symptoms, improved access to antiviral medications, and the government supports.
Highlighted with 84 tables and 80 figures, this 168-page report 鈥淕lobal Genital Herpes Treatment 麻豆原创 2022-2032 by Virus Type (HSV-1, HSV-2), Drug Type (Acyclovir, Valacyclovir, Famciclovir, Others), Route of Administration (Oral, Topical, Injection), Patient Gender (Female, Male), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Stores), and Region: Trend Forecast and Growth Opportunity鈥� is based on comprehensive research of the entire global genital herpes treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global genital herpes treatment market in every aspect of the classification from perspectives Virus, Drug Type, Route of Administration, Patient Gender, Distribution Channel, and Region.

Based on Virus Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� HSV-1
鈥� HSV-2

Based on Drug Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Acyclovir
鈥� Valacyclovir
鈥� Famciclovir
鈥� Other Drugs

By Route of Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Oral
鈥� Topical
鈥� Injection

By Patient Gender, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Female
鈥� Male

By Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Retail Pharmacies
鈥� Hospital Pharmacies
鈥� Online Pharmacies
鈥� Drug Stores

Geographically, the following regions together with the listed national/local markets are fully investigated:
鈥� North America (U.S., Canada, and Mexico)
鈥� Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
鈥� APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
鈥� South America (Brazil, Chile, Argentina, Rest of South America)
鈥� MEA (UAE锛孲audi Arabia锛� South Africa and Rest of MEA)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of all regional markets by country and split of each national market by Virus Type, Drug Type and Distribution Channel over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott
ADLEY FORMULATIONS
Aurobindo Pharma Ltd.
Avet Pharmaceuticals Inc.
Bausch Health Companies
Centurion Remedies
Cipla Ltd.
Eli Lilly & Company
Finecure Pharmaceuticals
GlaxoSmithKline Plc
Glenmark Pharmaceuticals
Macleods Pharmaceuticals
Medico Remedies
Merck & Co., Inc.
Novartis AG
Pfizer
Reddy's Laboratories
Sanofi SA
Teva Pharmaceutical Industries Ltd.
Torrent Pharma
Viatris Inc.
Zeelab Pharmacy
Zydus Pharmaceuticals, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of 麻豆原创 Research Methodology 13
1.2.2 麻豆原创 Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 麻豆原创 Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 麻豆原创 Overview and Dynamics 21
2.1 麻豆原创 Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the 麻豆原创 25
2.2 Major Growth Drivers 27
2.3 麻豆原创 Restraints and Challenges 31
2.4 Emerging Opportunities and 麻豆原创 Trends 34
2.5 Porter鈥檚 Fiver Forces Analysis 38
3 Segmentation of Global 麻豆原创 by Virus Type 42
3.1 麻豆原创 Overview by Virus Type 42
3.2 HSV-1 44
3.3 HSV-2 45
4 Segmentation of Global 麻豆原创 by Drug Type 46
4.1 麻豆原创 Overview by Drug Type 46
4.2 Acyclovir 48
4.3 Valacyclovir 49
4.4 Famciclovir 50
4.5 Other Drugs 51
5 Segmentation of Global 麻豆原创 by Route of Administration 53
5.1 麻豆原创 Overview by Route of Administration 53
5.2 Oral 55
5.3 Topical 56
5.4 Injection 57
6 Segmentation of Global 麻豆原创 by Patient Gender 58
6.1 麻豆原创 Overview by Patient Gender 58
6.2 Female 60
6.3 Male 61
7 Segmentation of Global 麻豆原创 by Distribution Channel 62
7.1 麻豆原创 Overview by Distribution Channel 62
7.2 Retail Pharmacies 64
7.3 Hospital Pharmacies 65
7.4 Online Pharmacies 66
7.5 Drug Stores 67
8 Segmentation of Global 麻豆原创 by Region 68
8.1 Geographic 麻豆原创 Overview 2022-2032 68
8.2 North America 麻豆原创 2022-2032 by Country 72
8.2.1 Overview of North America 麻豆原创 72
8.2.2 U.S. 76
8.2.3 Canada 81
8.2.4 Mexico 83
8.3 European 麻豆原创 2022-2032 by Country 85
8.3.1 Overview of European 麻豆原创 85
8.3.2 Germany 89
8.3.3 U.K. 91
8.3.4 France 93
8.3.5 Spain 95
8.3.6 Italy 97
8.3.7 Netherlands 99
8.3.8 Rest of European 麻豆原创 101
8.4 Asia-Pacific 麻豆原创 2022-2032 by Country 103
8.4.1 Overview of Asia-Pacific 麻豆原创 103
8.4.2 Japan 107
8.4.3 China 110
8.4.4 Australia 112
8.4.5 India 114
8.4.6 South Korea 116
8.4.7 Rest of APAC Region 118
8.5 South America 麻豆原创 2022-2032 by Country 120
8.5.1 Argentina 123
8.5.2 Brazil 125
8.5.3 Chile 127
8.5.4 Rest of South America 麻豆原创 129
8.6 MEA 麻豆原创 2022-2032 by Country 130
8.6.1 UAE 133
8.6.2 Saudi Arabia 135
8.6.3 South Africa 137
8.6.4 Other National 麻豆原创s 139
9 Competitive Landscape 140
9.1 Overview of Key Vendors 140
9.2 New Product Launch, Partnership, Investment, and M&A 143
9.3 Company Profiles 144
Abbott 144
ADLEY FORMULATIONS 146
Aurobindo Pharma Ltd. 147
Avet Pharmaceuticals Inc. 148
Bausch Health Companies 149
Centurion Remedies 150
Cipla Ltd. 151
Eli Lilly & Company 152
Finecure Pharmaceuticals 153
GlaxoSmithKline Plc 154
Glenmark Pharmaceuticals 155
Macleods Pharmaceuticals 156
Medico Remedies 157
Merck & Co., Inc. 158
Novartis AG 159
Pfizer 160
Reddy's Laboratories 161
Sanofi SA 162
Teva Pharmaceutical Industries Ltd. 163
Torrent Pharma 164
Viatris Inc. 165
Zeelab Pharmacy 166
Zydus Pharmaceuticals, Inc. 167
RELATED REPORTS 168

Companies Mentioned:

Selected Key Players:
Abbott
ADLEY FORMULATIONS
Aurobindo Pharma Ltd.
Avet Pharmaceuticals Inc.
Bausch Health Companies
Centurion Remedies
Cipla Ltd.
Eli Lilly & Company
Finecure Pharmaceuticals
GlaxoSmithKline Plc
Glenmark Pharmaceuticals
Macleods Pharmaceuticals
Medico Remedies
Merck & Co., Inc.
Novartis AG
Pfizer
Reddy's Laboratories
Sanofi SA
Teva Pharmaceutical Industries Ltd.
Torrent Pharma
Viatris Inc.
Zeelab Pharmacy
Zydus Pharmaceuticals, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.